Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Talk to the deal team
Aenza S.A.A. has completed a follow-on
Aenza S.A.A. has completed af follow-on to prepay part of a recently renegotiated bridge loan.Learn more
move UP has been acquired by Acture B.V.
move UP Gesellschaft für Gesundheitsmanagement mbH, an innovative provider of holistic corporate health management solutions, has been acquired by Acture B.V., a leader in welfare management. This acquisition represents a major step in Acture’s plans to expand into the German corporate health management sector.Learn more
Pampa Camarones has completed an IPO
Pampa Camarones SpA has successfully raised US$5 million through its stock market debut on ScaleX (Santiago Venture Exchange). These funds will be used to extend the mine life and incorporate the high-grade polymetallic project, Ciclón Exploradora.Learn more